← Back to headlines
Pfizer-backed Priovant Wins FDA Priority Review for Lead Asset
Priovant, a company backed by Pfizer, has received FDA priority review for its lead asset, indicating a fast-tracked evaluation process for a new drug.
3 Mar, 12:24 — 3 Mar, 12:24
ℹOnly 1 source covers this story
Read at source (1 outlet)
Related Stories
PH records 701,884 deaths in 2024; nearly half occur outside health facilities
just now
UPSC CSE 2025: Accident put her in a wheelchair and wiped her memory. Decade later, Kerala woman secures rank 483
19m ago
French prosecutors say January baby death unlikely linked to contaminated formula
21m ago
Policy must catch up with breast cancer burden
49m ago